Yu-nan Huang
Taitung, TNQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Cardiorenal Mortality and Safety Outcomes of GLP-1 Receptor Agonists in Type 2 Diabetes With BMI Below 27 kg/m2: A Target Trial Emulation.
Journal: Diabetes, obesity & metabolism
Published: May 18, 2026
Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.
Journal: American journal of therapeutics
Published: April 17, 2026
GLP-1 receptor agonists at immune checkpoint inhibitor initiation with immune-related and supportive-care outcomes in patients with cancer and overweight or obesity without diabetes: a target trial emulation.
Journal: Cancer immunology, immunotherapy : CII
Published: April 14, 2026
Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation.
Journal: Diabetes, obesity & metabolism
Published: January 13, 2026
Comparative 24-month cardiovascular outcomes and biomarker trajectories with semaglutide, empagliflozin, and sitagliptin in people with obesity and type 2 diabetes: a multicenter real-world study.
Journal: Therapeutic advances in endocrinology and metabolism
Published: December 20, 2025
Diabetes-type-specific thyroid safety of GLP-1 receptor agonists: evidence from a large real-world cohort.
Journal: Therapeutic advances in endocrinology and metabolism
Published: December 12, 2025
GLP-1 receptor agonist use during immune checkpoint inhibitor therapy is associated with mortality and Immune-Related adverse events across cancer types in People with type 2 Diabetes: A Target-Trial emulation.
Journal: Diabetes research and clinical practice
Published: November 07, 2025
Effectiveness of Pre-Transplant Dual GLP-1 Receptor Agonist and SGLT2 Inhibitor Therapy on All-Cause Mortality in Organ Transplantation Candidates with Obesity and Type 2 Diabetes: a Target-Trial Emulation.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: September 24, 2025
Loss of ZC3H12A Expression Is Linked to Higher Mortality Risk and Increased Lymphatic Metastasis in Oral Squamous Cell Carcinoma.
Journal: In vivo (Athens, Greece)
Published: July 25, 2025
Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
Journal: Communications medicine
Published: June 12, 2025
Comparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.
Journal: Communications medicine
Published: January 24, 2025
Unexpected cardiovascular risks of glucagon-like peptide-1 receptor agonist and aspirin co-administration in individuals with obesity, with and without type 2 diabetes: A propensity score matched cohort study.
Journal: Diabetes, obesity & metabolism
Published: October 01, 2024
Last Updated: 09/26/2026